LCTX is Lineage Cell Therapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $1.11. Market cap: $273M. Capital Quality Rank: 39/100 — Stagnant mediocrity.
Stock snapshot
| Price | $1.11 |
| Market cap | $273M |
| Sector | Healthcare |
| Exchange | ASE |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 39 / 100 · Stagnant mediocrity |
| ROIC (TTM) | -1118.3% |
| Revenue CAGR (3y) | -0.3% |
| Shareholder buyback yield | -13.00% |
| Altman Z-score zone | Distress |
About LCTX
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Related non-dividend companies
Other non-dividend stocks investors research alongside LCTX. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is LCTX's current stock price?
LCTX (Lineage Cell Therapeutics, Inc.) is currently trading at $1.11.
Does LCTX pay a dividend?
LCTX (Lineage Cell Therapeutics, Inc.) does not currently pay a regular dividend.
What is LCTX's Capital Quality Rank?
LCTX has a Capital Quality Rank of 39/100 — Stagnant mediocrity. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track LCTX in DiviDrip
Add LCTX to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search LCTX and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.